Stock listing

NASDAQ:INCY Incyte Corporation Stock

Home listing (NASDAQ) of Incyte Corporation

Follow Incyte Corporation into a list and get an email when it puts out news.

Share price · NASDAQ:INCY

$113.27 USD +1.70 (+1.5%)

Close on Oct 15, 2026

Incyte Corporation logo
Ticker
NASDAQ:INCY
Asset type
Stock
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Upcoming

  • Incyte (NASDAQ:INCY) Q3 2026 Earnings Call

    Thu, Oct 29, 2026 · 8:00 AM ET

    Register

Replays

  • Incyte (NASDAQ:INCY) Q2 2026 Earnings Call

    Tue, Jul 28, 2026 · 8:00 AM ET

    Watch Transcript

  • Incyte (NASDAQ:INCY) Q1 2026 Earnings Call

    Tue, Apr 28, 2026 · 8:00 AM ET

    Watch Transcript

  • Incyte (NASDAQ:INCY) Q4 2025 Earnings Call

    Tue, Feb 10, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Incyte to Report Third Quarter Financial Results

Oct 8, 2026

Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio

Sep 22, 2026

Incyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program

Sep 10, 2026

Incyte - Opzelura Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

Jul 30, 2026

Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates

Jul 28, 2026

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

Jul 17, 2026

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

Jul 13, 2026

Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio

Jul 6, 2026

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

Jun 26, 2026

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Jun 19, 2026

All Incyte Corporation news

Decks

Incyte Corporation on 6ix

News releases
55 in the last 12 months · 308 in all · newest Oct 8, 2026 · oldest 2019
Calls
26 calls with a replay · 26 with a transcript · latest Jul 28, 2026
Decks
31 decks · latest Jul 28, 2026

Where Incyte Corporation is listed

ListingExchangeCountryCurrency
NASDAQ:INCY · Home listing · This pageNASDAQUnited StatesUSD
gettex:ICYgettexGermanyEUR
Tradegate:ICYTradegateGermanyEUR
LSE:0J9PLSEUnited KingdomUSD
BMV:INCYBMVMexicoMXN
Frankfurt:ICYFrankfurtGermanyEUR
LS Exchange:896133LS ExchangeGermanyEUR
Lang & Schwarz:896133Lang & SchwarzGermanyEUR
Milan:1INCYMilanItalyEUR
BX Swiss:ICYBX SwissSwitzerlandCHF
B3:I1NC34B3BrazilBRL
BIVA:INCYBIVAMexicoMXN
EUROTLX:4INCYEUROTLXItalyEUR
Dusseldorf:ICYDusseldorfGermanyEUR
BOATS:INCYBOATSUnited StatesUSD
Hamburg:ICYHamburgGermanyEUR
Hanover:ICYHanoverGermanyEUR
Munich:ICYMunichGermanyEUR
Stuttgart:ICYStuttgartGermanyEUR
Turquoise:INCYNTurquoiseUnited KingdomUSD
Xetra:ICYXetraGermanyEUR

Log in to ask 6ix AI your own questions about Incyte Corporation.